NICE has recommended the genedrive (LON: GDR) CYP2C19-ID test for genotype-guided clopidogrel treatment in the NHS. It is the preferred platform for UK point-of-care testing for the management of ischemic stroke and transient ischaemic attack patients. It is advised that these patients should have a genetic test before antiplatelet treatment. The share price jumped 53.3% to 5.75p.
Guernsey-based APQ Global Ltd (LON: APQ) has published a trading statement reaffirming the end-February NAV of 23.97p/share. This was mainly due to the strong trading performance of US-based corporate advisory business Delphos International, where the valuation increased from $6.3m to $27m. The share price rose a further 18.2% to 6.5p.
Cambridge Nutritional Sciences (LON: CNS) is attending four major industry events in the current quarter. This is part of a campaign to increase awareness of the company’s personalised health and nutrition products. The share price improved 11.1% to 10p.
Oxford BioDynamics (LON: OBD) has opened a clinical testing facility in the UK for the EpiSwitch prostate screening blood test. This will shorten the turnaround time for tests. The share price increased 4.62% to 9.74p.
FALLERS
Cybersecurity consultancy and services provider Shearwater Group (LON: SWG) admits that it will make a loss in the year to March 2024. Revenues fell from £26.7m to £22.6m. Previously £32.5m was expected. There have been delays in contracts. The forecast 2024-24 revenues have been cut from £36.7m to £27.6m and the pre-tax profit estimate reduced from £1.7m to £600,000. The share price slumped 12.1% to 43.5p.
Canaccord Genuity has published its downgraded forecasts for plant-based polymers developer Itaconix (LON: ITX). It expects 2024 revenues $6.2m, compared with $9.5m previously and $7.8m for 2023. The forecast loss has been increased to $1.83m. The company will not move into profit in 2025 as previously expected. There should still be net cash of £3.8m at the end of 2025. Itaconix has not been able to agree terms with one of its main merchandising customers in North America. The share price fell further 8.72% to 178p.
Broker Peel Hunt (LON: PEEL) says full year revenues will improve from £82.3m to £85.5m, thanks to higher M&A income, but it will make a loss. RetailBook has raised outside finance and will be operated independently of Peel Hunt. The full year results will be published on 13 June. Market trading volumes are still low, and this is set to continue. Management says that the sentiment towards new admissions is improving. The share price slipped 5.14% to 120p.
Thor Explorations (LON: THX) has acquired interests in two exploration licences near to its Douta gold project in Senegal. It is paying $120,000 for up to 85% of the Douta West licence and $20,000 plus a $300,000 exploration spending commitment for up to 80% of the Sofita licence. This year’s production guidance for the Segilola mine is 95,000-100,000 ounces of gold. The share price declined 3.45% to 14p.
